Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUTLNASDAQ:EIDXNASDAQ:LEGNNASDAQ:PRNB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUTLAutolus Therapeutics$1.41-9.0%$1.93$1.39▼$5.84$375.19M2.071.40 million shs1.89 million shsEIDXEidos Therapeutics$122.21$123.21$28.39▼$132.54$4.75B-0.16128,113 shsN/ALEGNLegend Biotech$31.52-7.1%$36.40$30.17▼$60.87$5.79B0.191.20 million shs2.20 million shsPRNBPrincipia Biopharma$100.05$100.05$25.35▼$101.89$3.32B0.86729,676 shsN/ABeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUTLAutolus Therapeutics-9.03%-12.96%-18.50%-40.00%-75.18%EIDXEidos Therapeutics0.00%0.00%0.00%0.00%0.00%LEGNLegend Biotech-7.10%-10.07%-9.97%-3.13%-44.91%PRNBPrincipia Biopharma0.00%0.00%0.00%0.00%0.00%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAUTLAutolus Therapeutics3.0422 of 5 stars3.52.00.00.03.53.30.6EIDXEidos TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ALEGNLegend Biotech2.6763 of 5 stars3.53.00.00.03.01.70.6PRNBPrincipia BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUTLAutolus Therapeutics 3.00Buy$9.32560.99% UpsideEIDXEidos Therapeutics 0.00N/AN/AN/ALEGNLegend Biotech 2.92Moderate Buy$79.00150.63% UpsidePRNBPrincipia Biopharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest LEGN, EIDX, PRNB, and AUTL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/1/2025AUTLAutolus TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.003/21/2025AUTLAutolus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$8.00 ➝ $6.003/17/2025LEGNLegend BiotechMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$82.00 ➝ $80.003/12/2025LEGNLegend BiotechGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/12/2025LEGNLegend BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$73.00 ➝ $75.001/21/2025LEGNLegend BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$73.00 ➝ $73.001/13/2025AUTLAutolus TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 4/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUTLAutolus Therapeutics$10.12M37.07N/AN/A$0.64 per share2.20EIDXEidos Therapeutics$26.69M177.99N/AN/A$4.57 per share26.74LEGNLegend Biotech$627.24M9.23N/AN/A$6.88 per share4.58PRNBPrincipia Biopharma$35.16M94.50N/AN/A$10.95 per share9.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUTLAutolus Therapeutics-$208.38M-$0.86N/AN/AN/AN/A-63.65%-36.54%5/16/2025 (Estimated)EIDXEidos Therapeutics-$37.83M-$1.03N/AN/AN/AN/A-65.21%-53.04%N/ALEGNLegend Biotech-$518.25M-$0.48N/AN/AN/A-66.92%-29.69%-19.45%5/12/2025 (Estimated)PRNBPrincipia Biopharma-$53.79M-$2.09N/AN/AN/AN/A-23.08%-21.11%N/ALatest LEGN, EIDX, PRNB, and AUTL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/20/2025Q4 2024AUTLAutolus Therapeutics-$0.21-$0.09+$0.12-$0.09$2.98 million$0.03 million3/11/2025Q4 2024LEGNLegend Biotech-$0.39$0.07+$0.46$0.07$179.00 million$186.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUTLAutolus TherapeuticsN/AN/AN/AN/AN/AEIDXEidos TherapeuticsN/AN/AN/AN/AN/ALEGNLegend BiotechN/AN/AN/AN/AN/APRNBPrincipia BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUTLAutolus TherapeuticsN/A13.6913.69EIDXEidos Therapeutics0.1411.1011.10LEGNLegend Biotech0.274.984.90PRNBPrincipia BiopharmaN/A17.0117.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUTLAutolus Therapeutics72.83%EIDXEidos Therapeutics31.40%LEGNLegend Biotech70.89%PRNBPrincipia Biopharma95.54%Insider OwnershipCompanyInsider OwnershipAUTLAutolus Therapeutics25.70%EIDXEidos Therapeutics70.10%LEGNLegend Biotech0.02%PRNBPrincipia Biopharma16.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUTLAutolus Therapeutics330266.09 million197.71 millionOptionableEIDXEidos Therapeutics7038.87 millionN/ANot OptionableLEGNLegend Biotech1,070183.65 million182.60 millionOptionablePRNBPrincipia Biopharma6533.21 millionN/ANot OptionableLEGN, EIDX, PRNB, and AUTL HeadlinesRecent News About These CompaniesClass 3 girls basketball state championship: Fair Grove 39, Principia 33March 13, 2025 | stltoday.comPrincipia girls’ staggering defense halts Portageville in Class 3 state semifinal routMarch 12, 2025 | semissourian.comNya Walker's career day sparks Principia past Portageville in Class 3 girls semifinalMarch 12, 2025 | stltoday.comPrincipia embraces daily double as boys and girls basketball teams reach state tournamentMarch 12, 2025 | stltoday.comClass 3 girls basketball quarterfinal: Principia 47, Centralia 41March 9, 2025 | stltoday.comSanofi cuts programs tied to multibillion-dollar deals from pipelineJanuary 30, 2025 | fiercebiotech.comPrincipia Rotating 8 Tournament, semifinal: Principia 70, Eureka 24January 17, 2025 | stltoday.comBlue Storm Showdown: Principia 48, Mater Dei 41December 9, 2024 | stltoday.comCovenant Women Lose To Principia In Mountaintop Madness Finale; Men Lose At SewaneeNovember 9, 2024 | chattanoogan.comWestminster ends Principia's 18-game win streak to reach district finalNovember 7, 2024 | stltoday.comRecap: Lutheran South triumphs over PrincipiaOctober 26, 2024 | stltoday.comPrincipia College Recognized for Sustainability Practices On and Off CampusOctober 26, 2024 | riverbender.comSanofi adds BTK inhibitors to pipeline with $3.68bn Principia Biopharma acquisitionOctober 10, 2024 | pharmaphorum.comPrincipia College Recognized as a Top Performer in the 2024 Sustainable Campus IndexOctober 1, 2024 | riverbender.comFriendly fire: LC soccer teams sweep PrincipiaSeptember 15, 2024 | thetelegraph.comFORE Biotherapeutics Names Michael Byrnes as Chief Financial OfficerAugust 12, 2024 | finance.yahoo.comZimmerman, Dominguez switch roles at PrincipiaMay 14, 2024 | thetelegraph.comRecap: Principia topples O'Fallon ChristianMay 12, 2024 | stltoday.comRecap: Priory upends PrincipiaMay 5, 2024 | stltoday.comRecap: Lutheran South pounds PrincipiaApril 27, 2024 | stltoday.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLEGN, EIDX, PRNB, and AUTL Company DescriptionsAutolus Therapeutics NASDAQ:AUTL$1.41 -0.14 (-9.03%) Closing price 04/1/2025 04:00 PM EasternExtended Trading$1.40 -0.01 (-0.71%) As of 04/1/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.Eidos Therapeutics NASDAQ:EIDXEidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.Legend Biotech NASDAQ:LEGN$31.52 -2.41 (-7.10%) Closing price 04/1/2025 04:00 PM EasternExtended Trading$32.22 +0.70 (+2.20%) As of 04/1/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.Principia Biopharma NASDAQ:PRNBPrincipia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial to treat immune thrombocytopenic purpura. It is also developing PRN2246/SAR442168, an inhibitor, which has completed Phase I clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; PRN1371, a drug candidate that is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy Amazon Falls Back to a Key Support Line: Here's How to Play It Berkshire Hathaway Gains Defy Stock Market Slump Tech Sell-Off Makes Microsoft Stock Look Like a Steal Palantir Stock Builds Momentum on New Partnership Amprius Market Gets Amped Up on Growth Outlook 3 Buyable Stocks With Solid Bottoms Ready to Rebound Game-Changing News for Advanced Micro Devices Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
